The cytoplasmic malate dehydrogenase in neoplastic tissues; presence of a novel isoenzyme? by Grisham, M. B. et al.
Br. J. Cancer (1983), 47, 727-731
Short communication
The cytoplasmic malate dehydrogenase in neoplastic tissues;
presence of a novel isoenzyme?
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Malate dehydrogenase (MDH, EC 1.1.1.37)
catalyzes the reversible reduction of oxaloacetate to
malate in the presence of NADH. In eukaryotic
cells the enzyme is generally found to be present as
two distinct isoenzymes; one form is present in the
cellular cytosol and the other is present exclusively
in the mitochondria. These 2 isoenzymes form part
of a shuttle system (the malate-aspartate shuttle)
that functions as the major mechanism for the
transportation of reducing equivalents between the
cytosol and the mitochondria.
As part of our ongoing studies on the mechansim
of action and metabolic function of the malate
dehydrogenases (Bernstein et al. 1978; Bernstein &
Everse, 1978; Bernstein & Grisham 1978), we
recently investigated the kinetic properties of the 2
isoenzymes present in rat Novikoff hepatoma
tissues. These studies were initiated to evaluate
whether or not the enzymes in the malate-asparate
shuttle of tumour tissues are structurally and
functionally identical to those of normal tissues.
Fresh tumour or liver was homogenized with a
glass tissue homogenizer in 0.1 M potassium
phosphate buffer, pH 7.5, containing 0.25M
sucrose. The homogenate was centrifuged for 10
min at 10,000g to remove tissue debris. The
supernatant was then centrifuged for 30 min at
20,000g to obtain a high-speed supernatant that
contained the cytoplasmic enzymes. The
supernatantant did not contain any isocitrate
dehydrogenase activity or transhydrogenase activity
and was therefore judged to be free of
mitochondrial enzymes. This high-speed
supernatant was used without further fractionation
for the determination of the cytoplasmic MDH
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activity. Mitochondria were prepared by
resuspending the pellet in 0.1 M phosphate buffer,
pH 7.5, containing 0.25M sucrose and centrifuging
the suspension at 600g. The supernatant was then
centrifuged at 20,000g for 30 min, the precipitate
was collected and the washing procedure was
repeated once more. Finally, the precipitate was
suspended in phosphate buffer and sonicated for 1
min. The resulting solution was used for the assays
for the mitochondrial enzyme.
The assays were performed in 0.1M phosphate
buffer, pH 7.0, as described in the legend to Figure
1. Oxaloacetate and NADH solutions were freshly
prepared prior to use and kept in ice during the
analysis. The homogenates were also kept in ice
until the assays were completed. Assays were
performed at room temperature with a Beckman
Model 24 recording spectrophotometer.
A determination of the KM values for the
mitochondrial and the cytoplasmic enzyme yielded
the values listed in Table I. We found that the KM
values of the mitochondrial enzyme from the
hepatoma tissue were identical with the values
obtained with the enzyme from normal liver
mitochondria. The cytoplasmic enzymes also have
identical KM values for the coenzyme; however, the
Lineweaver-Burk plots for oxaloacetate were non-
identical. Whereas the KM value for oxaloacetate
obtained with the liver enzyme was -55 M, the
Lineweaver-Burk plot obtained with the hepatoma
enzyme displayed 2 slopes as illustrated in Figure 1.
One of the slopes corresponded with a KM value
that is approximately identical to that of the liver
enzyme, whereas the other slope yielded a KM value
for oxaloacetate of - 1 mM.
We interpret these data to indicate that Novikoff
hepatoma tissue contains 2 cytoplasmic enzymes
that possess MDH activity, one of which closely
resembles that present in the rat liver cytoplasm.
The other enzyme, having a KM of - 1 mM, is not
found in normal liver tissue.
The cytoplasmic MDH activity in the hepatoma
tissue with the same kinetic properties as the liver
enzyme could be due to a contamination of the
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Figure 1 Lineweaver-Burk plots of the cytoplasmic
malate dehydrogenase activity from rat liver (A) and
rat Novikoff hepatoma tissue (B) as a function of
oxaloacetate concentration. Assay mixtures contained
0.14mM NADH, the indicated amount of oxaloacetate
and an appropriate amount of the enzyme in 0.2M
phosphate buffer, pH 7.0. Total volume 3ml. Each
point represents the average of 3 determinations if the
obtained values were within 5% error. Additional
assays were done if a larger deviation was observed.
Table I KM values for the malate dehydrogenase
isoenzymes in normal and neoplastic rat tissues
Malate Oxaloacetate
(PM) (PM)
Rat Liver:
mitochondrial MDH 92 40
cytoplasmic MDH 55
Rat Novikoff Hepatoma:
mitochondrial MDH 90 40
cytoplasmic MDH 55; 1000
tumour tissue with normal tissue. To test this
possibility, we purified the Novikoff hepatoma cells
by growing them in tissue culture using a
Delbucco's modified essential medium, and trans-
ferring the culture until only neoplastic cells could
be detected in the culture. An extract of these cells
was subsequently used for the determination of the
cytoplasmic MDH activity. The obtained
Lineweaver-Burk plot was essentially identical to
that shown in Figure lB. It appears thus that
hepatoma cells contain the aberrant cytoplasmic
MDH as well as the normal enzyme. The specific
activity of the cytoplasmic MDH in rat livers was
found to vary from 20-300 umol NADH oxidized
min-1g-1 wet tissue. For the hepatoma tumours
this value ranged from 250-400pmolmin-'g-'.
These values are somewhat higher than those
reported by others (Weber et al., 1964; Shonk et
al., 1965), which is likely the result of our use of a
higher substrate concentration (6.6mM
oxaloacetate). The data indicate, however, that the
aberrant enzyme is not present in addition to
regular amounts of the normal enzyme, but some of
the normal enzyme is replaced by the aberrant
enzyme. Using the values for Vmax in Figure IB,
one calculates that the cytoplasmic MDH in the rat
hepatoma consists of -20% of the normal enzyme
and 80% of the aberrant enzyme.
To obtain further evidence for the existence of 2
distinct cytoplasmic enzymes, mitochondria-free
extracts of a rat Novikoff hepatoma as well as of
Novikoff hepatoma cells from tissue cultures were
prepared and subjected to electrophoresis on
Beckman cellulose acetate membranes at several pH
values. A normal rat liver extract was used as a
reference. The strips were stained using the
tetrazolium staining mixture described by Fine &
Costello (1963). Staining was continued for an
extended period of time in order to detect any
isoenzymes that might be present in small amounts.
However, no differences in isoenzyme distribution
between the tumour and the normal liver could be
detected. We concluded, therefore, that the aberrant
MDH is electrophoretically indistinguishable from
the normal cytoplasmic MDH.
An extensive search for the presence of the
aberrant enzyme in any normal rat tissue yielded
negative results. The presence of the unusual
enzyme was detected, however, in extracts of foetal
rat liver. Our data obtained thus far suggest that
the enzyme with the low affinity for oxaloacetate is
present during the early foetal stages, but gradually
disappears during the gestation period. None of the
aberrant enzyme appears to be present in the livers
of newborn rats.
We subsequently investigated whether or not the
aberrant MDH is present in other rat tumours as
well. The same differences in catalytic properties
were found when the cytoplasmic MDH activities
present in the livers of Sprague-Dawley and Buffalo
rats were compared with those of the hepatoma
H5123 (Morris minimal deviation) and the
hepatoma 19 (ethionine-induced rapidly growing
tumour). In these experiments KM values of - 1 mM
were found for oxaloacetate, using the tumour
extracts, whereas the KM values for the liver
extracts were 0.05mM. Similar changes wcrv found
in a virus-induced hamster lymphoma.
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A cytoplasmic MDH with characteristics similar
to those of the aberrant MDH is also present in
various human tumours. The various types of
tumours thus far investigated that contain the
unusual MDH are listed in Table II. The unusual
enzyme was absent in extracts of a granuloma and
a fibroma. The latter tissues yielded double
reciprocal plots with a single slope that closely
resembled that obtained with extracts from normal
liver tissues. The KM for oxaloacetate of the
cytoplasmic MDH from normal human liver
extracts was found to be 40 M. Double reciprocal
plots of the data obtained from all other tissues
listed in Table II yielded 2 slopes as shown in
Figure 2B. The KM value of the aberrant enzyme is
again -1 mM.
The unusual cytoplasmic MDH can also be
detected in the serum of animals and patients with
neoplastic disease. To demonstrate this, 2 assays
were done; one at an oxaloacetate concentration of
0.33 mM and the other at an oxaloacetate
concentration of 6.6mM. Both substrate
concentrations are well above the KM of the normal
cytoplasmic MDH and the rate of NADH
oxidation should be about independent of the
oxaloacetate concentration. Therefore the ratio of
the two rates should be close to unity. When such
assays were done on the sera of about 20 healthy
individuals, values between 0.8 and 1.0 were
obtained for the ratios of the two assays. Using sera
obtained from patients with neoplastic disease, we
obtained ratios between 2.0 and 3.0 (Table III),
indicating the presence of an enzyme with a high
KM value for oxaloacetate.
An analysis of serum samples for MDH activity
as described could be a useful tool in the early
diagnosis of certain malignant growths. In addition,
the technique could be used to evaluate the
effectiveness of various therapeutic treatments as
well as of the surgical removal of a malignancy.
Further details concerning these applications will be
presented elsewhere.
The question that remains to be answered
concerns the nature of the aberrant enzyme. Several
possibilities deserve consideration. The first
possibility is that the activity represents a hitherto
unknown MDH isoenzyme that is only present
during embryonic development and in certain
neoplasms. The existence of such a novel isoenzyme
would explain our present observations. The
presence of the isoenzyme can readily be
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Figure 2 Lineweaver-Burk plots of the cytoplasmic
malate dehydrogenase activity from human liver (A)
and human adenocarcinoma tissue (B) as a function of
oxaloacetate concentration. Assays mixtures were as
described in the legend of Figure 1.
Table II KM for oxaloacetate in tissue homogenates of
human origin
Tissue KM (mM)
Adenocarcinoma (Breast) 1.0, 1.2
Adenocarcinoma (Colon) 1.0
Adenocarcinoma (Uterus) 1.0
Squamous cell carcinoma (Throat) 0.9
Lymphocytic leukaemia 1.1
Granuloma 0.035
Fibroma 0.048
Liver 0.04
Table III KM for oxaloacetate in sera from cancer
patients
Tumour KM (mM) Ratio*
Lymphocytic leukaemia 0.9 2.0
Adenocarcinoma (Liver) 1.1 2.1
Adenocarcinoma (Colon) 1.0 2.1
Adenocarcinoma (Stomach) 1.0 2.0
Adenocarcinoma (Ovary) 1.0 2.0
Normal 0.05 1.0
*Ratio= Reaction velocity at 6.6mM OAA divided
by velocity at 0.33mM OAA.
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demonstrated by its catalytic activity, but is
electrophoretically indistinguishable from the native
isoenzyme. It is very difficult to see, however, how
the presence of a MDH isoenzyme with a very high
KM for oxaloacetate can provide a metabolic
advantage to rapidly growing cells (Weber, 1977).
A second possibility is that the activity results
from an enzyme that has some non-specific malate
dehydrogenase activity. Lactate dehydrogenase
would be a likely candidate for this, since it is
closely related to MDH in many respects. However,
the possibility that lactate dehydrogenase is acting
as a malate dehydrogenase isoenzyme can be ruled
out on the following observations:
(a) Lactate dehydrogenase activity is
electrophoretically distinguishable from MDH
activity.
(b) The aberrant activity was undetectable in
normal tissues, indicating that the aberrant
activity must be present in much higher
concentrations in tumour tissues than in normal
tissues. We found that the lactate
dehydrogenase activity in various tumour
tissues tested is not more than 2-5 times higher
than that in normal tissues, where it is of course
present in appreciable amounts.
(c) The KM of lactate dehydrogenase for
oxaloacetate varies from 1.75mM at pH 6.0 to
4.9mM at pH 7.4 (Parker & Holbrook, 1981),
which is considerably higher than the value of
1.0mM at pH 7.0 that we found for the
aberrant enzyme.
A third possibility is that the oxaloacetate is
partially converted to pyruvate by a decarboxylase
present in the tumour tissues. The pyruvate thus
formed would readily be reduced by the lactate
dehydrogenase present in the extracts and thus
contribute to the observed decreases in NADH in
our assays. The fact that the KM values that we
obtained for the MDH from normal tissues (and for
tumour tissues at low oxaloacetate concentrations)
are similar to the values obtained by others
(Englard, 1969; Kitto & Kaplan, 1966) with highly
purified MDH indicates that significant
decarboxylation of the oxaloacetate is not a
problem at the low oxaloacetate concentrations. In
fact, if the aberrant activity resulted from the
decarboxylation of oxaloacetate to pyruvate, we
would in effect have measured the KM of the
decarboxylase for oxaloacetate as being 1.0mM,
since the KM of lactate dehydrogenase for pyruvate
is very low (Everse & Kaplan, 1973). The fact that
the oxaloacetate concentration in tumour cells as
well as normal cells is far below 1 mM again raises
a question as to the possible metabolic advantage
that such a decarboxylase would provide for the
tumour cell.
It is clear that the question addressed by this
article must remain unanswered until the enzyme
that promotes the aberrant activity has been
purified and fully characterized. The finding of an
isoenzyme with an increased KM in tumour tissues
would not be unique, however. Weber et al. (1964)
showed that the phosphoglucomutase in rapidly
growing hepatomas has a KM for glucose-i-P that
is 3-6 times higher than the KM value found for the
normal (liver) enzyme. It is thus possible for certain
tumour cells to synthesize enzymes different from
those produced by normal cells, thus reflecting
changes in genetic expression. More detailed
information concerning such changes in enzyme
characteristics could be useful both for diagnostic
and for chemotherapeutic purposes.
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